| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4b2073d47e226063dd7950d434be9e0f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b4f2af3b7e02ef76dbb86caf105e360b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ffcd9cdc8ef9bfad9943a80e4fdd312d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a988a93dce0d942de0ff16b0c640c2ec
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a5930ed2292d797612e6caf1133d1e4b |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-336
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-336 |
| filingDate |
2016-09-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2eafb04ae66f4f754dfae3d250af9900
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0805ce76fa4212be2306fe1d46617632
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_872d617250dabc3912b9e38ceba522dc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c43f6d4ca0fba2417239c94cfe0e1dc4 |
| publicationDate |
2017-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2017042634-A2 |
| titleOfInvention |
Use of dianhydrogalactitol or derivatives and analogs thereof for treatment of non-small-cell lung carcinoma, glioblastoma, and ovarian carcinoma by induction of dna damage and stalling of cell cycle |
| abstract |
The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of glioblastoma, non-small-cell lung carcinoma (NSCLC) and ovarian cancer, as well as other types of malignancy, including brain metastases of NSCLC. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N 7 methylation and inter-strand crosslinks that can induce double-stranded breaks in DNA. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide, cisplatin, and tyrosine kinase inhibitors; the drug acts independently of the MGMT repair mechanism. Dianhydrogalactitol can be used together with other anti-neoplastic agents and can possess additive or synergistic effects. Dianhydrogalactitol can be used for treatment of leptomeningeal carcinomatosis. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10441654-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111358948-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018204323-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3589282-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022226277-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11717505-B2 |
| priorityDate |
2015-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |